PRESS RELEASE : QUANTRO Therapeutics appoints Dr. Elmar Maier as Independent Board Chairman

DGAP-News: QUANTRO Therapeutics GmbH / Key word(s): Personnel 
QUANTRO Therapeutics appoints Dr. Elmar Maier as Independent Board Chairman 
2021-04-30 / 10:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
QUANTRO Therapeutics appoints Dr. Elmar Maier as Independent Board Chairman 
Vienna, Austria, 30 April 2021: QUANTRO Therapeutics GmbH today announced the appointment of Dr. Elmar Maier as 
Independent Chairman of its Board. 
Elmar has a long-standing track record as a seasoned dealmaker in the life science industry. Over the last 26 years, he 
has co-founded several biotech companies (including GPC Biotech AG and iOmx Therapeutics AG) and held C-level positions 
on multiple management teams in private and public biotech companies. He has helped biotech companies to establish 
large R&D collaborations generating several hundred million dollars cash up-front, raise significant equity funding and 
execute M&A transactions. Elmar holds a degree in chemistry and obtained his Ph.D. from the University of Konstanz, 
Germany. He was a scientist at the ICRF Laboratories in London and Department Head at the Max Planck Institute for 
Molecular Genetics in Berlin. In addition to QUANTRO, he has served as a Board member for several biotech companies. 
Dr. Dieter Nachtigall, Chief Executive Officer of QUANTRO, said: "We are delighted to have Elmar join the QUANTRO 
Board. He is a highly successful and respected leader in the industry, and we will benefit greatly from his strategic 
advice and strong business development expertise. Additionally, his knowledge of effectively building and growing drug 
discovery companies will be invaluable as we move QUANTRO forward. Throughout his career, Elmar has shown strong 
leadership capabilities and an innovative spirit, making him an excellent fit for QUANTRO. I look forward to working 
closely with him and the other Board members as we carry out our mission of identifying and developing new anti-cancer 
agents with breakthrough potential." 
Dr. Elmar Maier, Chairman of the Board of QUANTRO, added: "Transcription factors are key regulators of gene expression 
and represent a unique class of drug targets, but direct modulation by small molecules until now has been notoriously 
difficult. I am very excited about QUANTRO's proprietary drug discovery platform combining genome engineering, next-gen 
cell-based compound screening, metabolic RNA sequencing and bioinformatics to rapidly identify novel drug candidates 
targeting such central transcriptional activities. I look forward to working with the QUANTRO team to build the company 
through a combination of an internal drug development pipeline and partnerships with leading pharmaceutical companies." 
Contact 
QUANTRO Therapeutics GmbH 
Dr. Dieter Nachtigall, CEO 
Mail: [e-mail] 
www.quantro-tx.com 
Media Contact 
MC Services AG 
Katja Arnold, Andreas Jungfer, Shaun Brown 
Phone: [phone] 
Mail: [e-mail] 
About QUANTRO Therapeutics GmbH 
QUANTRO Therapeutics ("QUANTRO") is a drug discovery company focused on developing novel therapeutics interfering with 
disease-causing transcriptional programs in cancer and other diseases. QUANTRO's goal is to build a highly innovative 
drug discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify and 
develop drug candidates interfering with transcriptional regulators. The first area of focus will be on 
cancer-associated transcription factors, which so far have been unamenable to pharmacologic intervention. QUANTRO is a 
spin-off of the Institute of Molecular Biotechnology ("IMBA") and the Research Institute of Molecular Pathology 
("IMP"), both located in Vienna, Austria. Seed investors are the Boehringer Ingelheim Venture Fund and Evotec. 
www.quantro-tx.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-04-30 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1190938 2021-04-30

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1190938&application_name=news

(END) Dow Jones Newswires

April 30, 2021 04:00 ET (08:00 GMT)